Tim Harrison, MD

Head of Inhaled Asthma Portfolio
BioPhamaceuticals, Global Medical Affairs, AstraZeneca Cambridge, United Kingdom, United Kingdom

Poster(s):

• (404) Efficacy of as-needed albuterol–budesonide versus albuterol on systemic corticosteroid exposure in participants with mild asthma: BATURA prespecified analysis
  Wednesday, October 29, 2025

• (407) As-needed albuterol–budesonide decreases risk of severe asthma exacerbation in the first three months post-randomization compared to albuterol in patients treated for moderate-to-severe asthma: MANDALA post-hoc analysis
  Wednesday, October 29, 2025